A randomized control trial that examined the effects of dupilumab, a monoclonal antibody to the α subunit of the IL-4 receptor (IL-4Rα) that inhibits signaling of IL-4 and IL-13, in patients with CRSwNP versus placebo have demonstrated significant improvements in polyp size, disease-specific SNOT-22 (22-item Sinonasal Outcome Test) score, and objective olfactory function (104). This evidence concerns the gene IL13 and polyp.